Neuralink occupies a rare position in the private-company universe: it sits at the intersection of neuroscience, consumer health, and defense-adjacent technology, yet it has never raised a public round, issued a prospectus, or given the market a clean anchor for valuation. In a private market marketplace, that combination creates an unusually noisy secondary market — one where bid-ask spreads can swing 20 to 30 percent in the same week depending on which clinical update circulates through investor networks. If you're still building foundational context on how pre-IPO investing and secondary pricing dynamics work across complex private companies, review the complete guide to pre-IPO investing before interpreting volatility in names like Neuralink.
If you are considering a secondary purchase, the central question is not whether Neuralink is interesting. It is whether the current asking price already prices in the milestones most likely to happen next, and whether the structure you are buying through actually gives you the exposure you think you are getting.
Why secondary supply is thin
Neuralink has never run a widely publicized tender offer. That matters because tenders are often the main mechanism through which early employees and seed investors liquidate at scale. Without one, sellers are almost entirely drawn from two groups: former employees who have left the company and want liquidity, and early investors who have held long enough to want portfolio rebalancing.
Both groups face stiff transfer restrictions. Neuralink's shareholder agreements — consistent with Elon Musk's other private ventures — include right-of-first-refusal (ROFR) provisions that give the company (and sometimes existing major shareholders) the right to step in and match any proposed secondary sale before it closes. When the company exercises ROFR, the buyer loses the trade after potentially weeks of diligence. That friction deters casual sellers from listing in the first place.
The practical effect: sellers who do come to market often ask for a premium to compensate for the hassle and for the residual risk that the company claws back the transaction. Buyers who do not understand ROFR mechanics can find themselves bidding against a ghost — the company itself — at the finish line.
How to read the current pricing environment
Secondary marks on Neuralink have climbed in 2025 and into 2026 on the back of the PRIME study's first published data showing sustained motor-signal decoding in paralyzed patients. That clinical signal is real. The question for secondary pricing is how much of the next two or three years of anticipated clinical progress is already embedded in today's ask.
A useful framework: strip out the narrative and focus on the last 409A valuation the company filed, then ask how many years of assumed growth at what discount rate get you from that 409A number to the secondary ask. If the implied compound annual growth rate needed to justify the ask requires the company to clear FDA breakthrough-device approval, scale a manufacturing line, and achieve commercial reimbursement all within five years, you are paying for outcomes, not fundamentals. That is not inherently wrong — venture-style risk-taking is exactly what this asset class is — but it should be a conscious choice.
A secondary mark is a transaction price, not an appraisal. It reflects the most motivated buyer and the most motivated seller who happened to find each other. It is not the same as the 409A, which is a good-faith independent appraisal used for tax purposes, nor is it the same as the last primary round price, which was set by a lead investor doing full diligence.
Structure choices: SPV versus forward contract
Most secondary buyers access Neuralink through one of two vehicles. The first is a special-purpose vehicle (SPV): a legal entity formed to hold the economic interest in the underlying shares, with the SPV sponsor handling the ROFR process and transfer paperwork. The second is a forward contract: a binding agreement where the seller agrees to deliver shares (or their cash equivalent) at a defined price on a future date, typically tied to a liquidity event.
For Neuralink specifically, direct transfers are rare because the company's transfer-approval process is slow and selective. Most buyers end up in an SPV. That means you need to read the SPV's governing documents carefully: look at fee waterfall, the sponsor's track record clearing Neuralink ROFR specifically, and what happens to your position if a tender offer arises before the SPV dissolves.
Key diligence questions to answer before you bid
- What is the implied valuation at the ask price, and what assumptions does it require about the regulatory pathway and timeline?
- Has the SPV sponsor successfully closed Neuralink transfers before, or is this their first attempt with this issuer?
- What is the ROFR waiver track record? Ask specifically whether the company has exercised ROFR on recent transactions.
- What are the total fees — management fee plus carry — and over what holding period do those fees materially dilute your return?
- Is the underlying position options, common stock, or preferred? Each has a different liquidation preference stack on exit.
- Does the SPV have a defined wind-down trigger, or could you be in the vehicle indefinitely if no liquidity event occurs?
None of these questions have automatic right or wrong answers. They exist to make sure you are buying what you think you are buying, at a price that reflects the risk you are actually taking on.
What a reasonable position size looks like
Pre-IPO secondaries are illiquid by nature. Neuralink is among the more illiquid names in the private market because the transfer approval process is slow, the tender market is thin, and no secondary sale is guaranteed to close without ROFR intervention. Standard portfolio-construction guidance — which is general educational context, not advice — places highly illiquid single-name positions at 2 to 5 percent of a total investable portfolio, with concentration risk increasing meaningfully above 10 percent.
Limen Markets lists Neuralink among its 28 issuers with hourly supply refresh. When a position clears to the marketplace, it means the seller has been confirmed and ROFR navigation begins in parallel with execution — reducing the fall-through risk that plagues less coordinated platforms. Minimum indication size is $25,000. Live asks on Neuralink pre-IPO shares sit alongside the rest of the active book on the marketplace.
If you are ready to review the Neuralink secondary market, visit the marketplace. If you want to understand how ROFR mechanics work in detail before you commit, read the ROFR navigation guide. To see where Neuralink fits in the broader AI pre-IPO market, read our 2026 market map.